Amgen hits a snag in its plot to challenge AbbVie’s blockbuster Humira

Damian Garde

, at work on a biosimilar of AbbVie's best-selling treatment, got an unfavorable decision from U.S. regulators that could delay the launch of its take on .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS